A very promising cure for blood disorders with a one-time treatment

Blood disorders are diseases that affect the production or function of blood cells, such as red blood cells, white blood cells, or platelets. Some of the most common blood disorders are sickle cell anemia and beta thalassemia, which are caused by mutations in the genes that code for hemoglobin, the protein that carries oxygen in red blood cells.

Sickle cell anemia and beta thalassemia are inherited diseases that affect millions of people around the world, especially in regions where malaria is prevalent. People with sickle cell anemia have abnormal hemoglobin that makes their red blood cells rigid and sickle-shaped, which can block blood vessels and cause pain, infections, organ damage, and stroke. People with beta thalassemia have reduced or absent production of beta-globin, one of the components of hemoglobin, which leads to severe anemia, bone deformities, and enlarged spleen and liver.

The current treatments for these blood disorders are limited and often require lifelong blood transfusions, medication, or bone marrow transplantation, which can have serious side effects and complications. However, a new and promising approach is emerging that could offer a permanent cure for these diseases with a one-time treatment: CRISPR gene editing.

CRISPR is a technology that allows scientists to make precise changes in the DNA of living cells. CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats, which are sequences of DNA that bacteria use to defend themselves against viruses. CRISPR works by using a protein called Cas9, which acts like a pair of scissors, and a guide RNA, which acts like a GPS, to find and cut a specific target in the DNA. By delivering the CRISPR components to the cells, scientists can edit the DNA and correct the mutations that cause diseases.

In the case of sickle cell anemia and beta thalassemia, the CRISPR strategy is to boost the production of fetal hemoglobin, a type of hemoglobin that is normally present only in fetuses and newborns, but can also compensate for the defective adult hemoglobin in people with blood disorders. Fetal hemoglobin is controlled by a gene called BCL11A, which acts like a switch that turns off fetal hemoglobin and turns on adult hemoglobin after birth. By using CRISPR to disrupt or silence the BCL11A gene, scientists can reactivate the fetal hemoglobin and restore the normal function of the red blood cells.

The CRISPR treatment for blood disorders involves the following steps:

- First, the patient's blood stem cells are collected from the bone marrow or the blood.
- Second, the blood stem cells are treated with CRISPR in the laboratory to edit the BCL11A gene and increase the fetal hemoglobin.
- Third, the patient receives chemotherapy to destroy their own blood stem cells and make room for the edited ones.
- Fourth, the patient receives a transplant of their own edited blood stem cells, which will produce healthy red blood cells with fetal hemoglobin.

The CRISPR treatment for blood disorders has shown promising results in clinical trials, with several patients reporting improved symptoms, reduced or eliminated transfusions, and no serious adverse events. The treatment is expected to be safe and durable, as the edited blood stem cells can self-renew and produce blood cells for the rest of the patient's life. The treatment is also expected to be accessible and affordable, as it uses the patient's own cells and does not require a matched donor.

The CRISPR treatment for blood disorders is a revolutionary advance that could transform the lives of millions of people who suffer from these debilitating diseases. By using the power of gene editing, scientists can correct the root cause of the diseases and provide a one-time cure that could last a lifetime.

Get your free consultation from specialists of VIP Medical Service to discover the latest solutions for treatment.

Sources:
frontiersin.org
nature.com
thehealthsite.com